Source link : https://www.newshealth.biz/health-news/combination-slows-metastatic-crc-progression-better-than-single-immunotherapy/
SAN FRANCISCO — An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study. Median progression-free survival (PFS) had yet to be reached with nivolumab (Opdivo) plus ipilimumab (Yervoy) after 47 months of follow-up as compared with a median of 39.3 months with […]
Author : News Health
Publish date : 2025-01-27 17:11:13
Copyright for syndicated content belongs to the linked Source.
Categories